Unexpectedly high toxicity of MACOP‐B in young patients with low grade lymphoma

Abstract
We report the results of treatment with MACOP‐B in 11 young patients with low grade lymphoma (LGL). Complete remission was obtained in 4 (57%) and partial remission in 3 (42.8%) of 7 evaluable patients. However, this aggressive chemotherapy has not offered any advantage because of an unacceptably high treatment‐related morbidity and mortality (17%). Serious infection during neutropenia was the most common complication.